- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04532359
Measurement of Implant Stability by Resonance Frequency Analysis in Patients Treated for an Upper Aero-digestive Tract Cancer (STABICAN)
STABICAN : Measurement of Implant Stability by Analysis of the Resonance Frequency in Patients Treated for Cancer of the Upper Aero-digestive Tract
Study Overview
Detailed Description
Oral implantology is widely used during prosthetic rehabilitation in healthy patients but also in patients presenting cancers of the upper aero-digestive tract.
Systems for measuring implant stability using resonance frequency analysis exist and are used clinically by some practitioners, such as the Ostell® system from W&H. These systems make it possible to determine the osseointegration of the implant, and thus the appropriate time to insert the implant, by comparing the value obtained with average values.
Implant survival rates are lower for implants placed in irradiated bone, with an implant stability quotient value identical to implant placement but lower after osseointegration. Only one study shows implant stability quotient values> 60 with a success rate of 100% at 41 months on implants placed in patients having received radiotherapy. However, no clinical study has investigated the kinetics of osseointegration and the stability of implants placed on a microanastomosis fibula flap as part of aesthetic and prosthetic reconstruction after cancer of the upper aero-digestive tract.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ellen BLANC
- Phone Number: +33 4.78.78.2967
- Email: ellen.blanc@lyon.unicancer.fr
Study Contact Backup
- Name: Anne-Gaëlle CHAUX-BODARD, MD
- Phone Number: +33 4.78.78.29.59
- Email: anne-gaelle.bodard@lyon.unicancer.fr
Study Locations
-
-
-
Lyon, France, 69008
- Recruiting
- Centre Léon Bérard
-
Contact:
- Anne-Gaëlle CHAUX-BODARD, MD
- Phone Number: +33 4.78.78.29.59
- Email: anne-gaelle.bodard@lyon.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with squamous cell carcinoma of the upper aero-digestive tract (oral cavity, oropharynx, hypopharynx
- Patient having been treated by external radiotherapy and/or having benefited from a microanastomosis fibula flap
- Patient going to undergo a surgical intervention with placement of dental implant(s) in an irradiated area or in the microanastomosis fibula flap
- Non-opposition to the study
Exclusion Criteria:
- Patient having difficulties speaking and understanding French
- Patient under tutorship or curatorship
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evolution of implant stability in patients treated for cancer of the upper aero-digestive tract between placement and 3 months after placement
Time Frame: At 3 months after implant placement
|
Measure with Osstell Beacon device (Implant Stability Quotient : value from 1 to 100)
|
At 3 months after implant placement
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the association between the type of bone (maxilla/mandible and fibula) and implant stability
Time Frame: At 3 months after implant placement
|
Correlation between the type of bone (maxilla / mandible and fibula) and implant stability
|
At 3 months after implant placement
|
|
Evaluation of the correlation between the irradiation dose received at the implant site and implant stability
Time Frame: At 3 months after implant placement
|
Correlation between the irradiation dose received at the implant site and implant stability
|
At 3 months after implant placement
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne-Gaëlle CHAUX-BODARD, MD, Centre Léon Bérard
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- STABICAN - ET20-099
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.